Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06656091

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

Simmitinib Versus Investigator's Choice of Chemotherapy for Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma : a Randomised, Open-label, Multicentre, Phase 3 Study

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd

Conditions Advanced Oesophageal Squamous Cell Carcinoma

Interventions investigator's choice of chemotherapy,include docetaxel or irinotecan. simmitinib

Updated 1 time since 2024 Last updated: Oct 23, 2024 Started: Oct 31, 2024 Primary completion: Jan 30, 2027 Completion: Jan 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Advanced Oesophageal Squamous Cell Carcinoma and is currently actively recruiting participants. Shanghai Runshi Pharmaceutical Technology Co., Ltd leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Data source: Shanghai Runshi Pharmaceutical Technology Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.